CONMED (CNMD) Q2 2024 earnings summary

Executive summary

• Q2 2024 sales reached $332.1 million, up 4.5% year-over-year (5.2% in constant currency), marking a record high, with strong general surgery growth and net income more than doubling to $30.0 million.

• GAAP diluted EPS was $0.96, up from $0.43 in Q2 2023; adjusted EPS was $0.98, up 18.1%.

• Gross profit margin improved to 55.3% from 53.7% year-over-year, and operating margin rose to 14.2% from 8.6%.

• Supply chain challenges, especially in orthopedics, led to missed sales opportunities and a downward revision of full-year guidance.

• General Surgery, particularly AirSeal, showed strong demand and growth, with no anticipated supply issues.

Financial highlights

• U.S. sales grew 6.1% and international sales 4.0% year-over-year in Q2; international comprised 44% of total revenue.

• General Surgery revenue increased 9.4% globally, with U.S. up 8.9% and international up 10.5%; Orthopedic Surgery declined 0.9%.

• Single-use products accounted for 84% of Q2 revenue, growing 6.2% year-over-year in constant currency.

• Adjusted gross margin improved by 90 basis points to 55.3% in Q2.

• Cash flow from operations was $43.3 million, up from $26.7 million in Q2 2023.

Outlook and guidance

• Full-year 2024 revenue guidance revised to $1.305–$1.315 billion, reflecting 5–6% constant currency growth.

• Adjusted EPS guidance set at $3.95–$4.02, representing 14.5–16.5% growth.

• Gross margin expected to reach 57% by Q4, with sequential improvement projected.

• Foreign currency expected to negatively impact revenue by $5M–$10M for the year.

• Q3 expected to be slower, with Q4 growth picking up as supply chain issues are resolved.